|
Match
|
Document |
Document Title |
|
|
6630454 |
Method and pharmaceutical composition for the treatment of cancer
A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.
|
|
|
6627662 |
3-amino-propoxyphenyl derivatives (I)
Compounds of formula (Ia) as potent, β 1 -specific beta blockers with a short duration of action in the systemic circulation, wherein R is 3′,4′-dimethoxyphenyl. R 1 is hydrogen, and R 2 is...
|
|
|
6610705 |
Process for the preparation of diaryl naphthyl methanes
The invention relates to novel diaryl naphthyl methane compounds having general formula I as shown herein below, and said compounds useful in the treatment of esterogen related disease or syndrome,...
|
|
|
6599920 |
Naphthalene compounds, intermediates, formulations, and methods
This invention relates to the field of pharmaceutical and organic chemistry and provides naphthalene compounds, intermediates, formulations, and methods.
|
|
|
6599921 |
Non-steroidal estrogen receptor ligands
Novel non-steroidal estrogen receptor ligands and methods of synthesis are disclosed. The novel molecules are intended for use in therapeutic preparations for the treatment of estrogen receptor...
|
|
|
6576636 |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.
|
|
|
6576645 |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH 3 , OH; or where...
|
|
|
6569904 |
Agent for lowering endothelin levels
The present invention relates to a new medical use of triphenylethylene antiestrogen toremifene or a phamaceutically acceptable thereof for lowering endothelin-1 levels in mammals, and for the...
|
|
|
6562871 |
Dry granulation of pharmaceutical formulation comprising mexiletine
Compaction of mexiletine hydrochloride crystals is described, which provides a powder suitable for use in capsules without use of organic solvents.
|
|
|
6559186 |
Compositions and methods of treatment of sympathetically maintained pain
Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an α-1-adrenergic antagonist, α-2-adrenergic agonist, or other...
|
|
|
RE38115 |
Dextromethorphan and an oxidase inhibitor for treating intractable conditions
Methods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising...
|
|
|
6555532 |
Method of treating alopecia
A method of enhancing hair growth or treating alopecia in a subject uses topically administered estrogen receptor antagonists. Pharmaceutical formulations comprising estrogen receptor antagonists...
|
|
|
6518314 |
Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted,...
|
|
|
6515027 |
Substituted benzanilides as CCR5 receptors ligands, antiinflammatory agents and antiviral agents
This invention relates to substituted benzanilides which are ligands, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease...
|
|
|
6486146 |
Cancer accelerants and phase synchronization methods
The invention discloses compositions and methods for increasing chemotherapeutic specificity to endocrine dependent cancers, and reducing systemic toxicity, through administration of endocrine...
|
|
|
6469065 |
Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic...
|
|
|
6451817 |
Alpha-substituted-1-benzyl-napthyls
This invention relates to the fields of pharmaceutical and organic chemistry and provides novel 1-benzyl-naphthyls which are α-substituted with ether, thioether, amino, hydrazino, cyano or halo...
|
|
|
6399608 |
Combination of a GABA-A α 2/3 agonist and a selective serotonin reuptake inhibitor
A pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound, which is a modulator of the benzodiazepine binding site of the human GABA A receptor, having a binding affinity...
|
|
|
6391892 |
Naphthyl pharmaceutical compounds
The present invention provides a compound of formula I wherein R 1 is H, OH, halo, OCO(C 1 -C 6 alkyl), OCO(aryl), OSO 2 (C 4 -C 6 alkyl), OCOO(C 1 -C 6 alkyl), OCOO(aryl), OCONH(C 1 -C 6 ...
|
|
|
6391920 |
Methods of treating androgen deficiency in men using selective antiestrogens
Male menopause is characterized by significant decreases in serum levels of bioavailable androgens. The administration of antiestrogens to men experiencing male menopause can remedy the relative...
|
|
|
6387958 |
Remedy for autoimmune diseases
Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.
|
|
|
6387956 |
Methods of treating obsessive-compulsive spectrum disorders
A method of treating an obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual.
|
|
|
6384053 |
α-substituted-1-benzyl-napthyls
This invention relates to the fields of pharmaceutical and organic chemistry and provides novel 1-benzyl-naphthyls which are α-substituted with ether, thioether amino, cyano or halo that are...
|
|
|
6358944 |
Methods and compositions for treating generalized anxiety disorder
The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating Generalized Anxiety Disorder. The present...
|
|
|
6355632 |
Naphthyl compounds, intermediates, compositions, and methods
The present invention provides pharmaceutically active compounds formula I wherein R 1 is —H, —OH, —O(C 1 -C 4 alkyl), —OCOC 6 H 5 , —OCO(C 1 -C 6 alkyl), or —OSO 2 (C 2 -C 6 ...
|
|
|
6346518 |
Itraconazole and saperconazole stereoisomers
The present invention is concerned with the stereoisomeric forms of itraconazole (X=Cl) and saperconazole (X=F), which may be represented by the formula and the pharmaceutically acceptable acid...
|
|
|
6338837 |
Compositions and methods for inhibiting nematocyst discharge
Compositions for inhibiting nematocyst or polar capsule discharge are provided in the form of an effective amount of antihistamine, an effective amount of antihistamine and an effective amount of...
|
|
|
6333358 |
Aryloxyaniline derivatives
An aryloxyaniline derivative represented by the formula: ##STR1## wherein Ar 1 and Ar 2 are each a substituted or unsubstituted phenyl group, pyridyl group or naphthyl group, R 1 is a hydrogen...
|
|
|
6284799 |
Cancer treatment
The present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the...
|
|
|
6258802 |
Corticoid therapy
Treatments in which a progestational corticoid active compound is administered are improved by additionally administering a selective estrogen receptor modulator.
|
|
|
6235792 |
Phosphate salt of isopropyl-methyl- [2-(3-n-propoxyphenoxy)ethyl]amine
The present invention relates to a novel monophosphate salt of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine. Moreover, the present invention also relates to a process for the preparation of...
|
|
|
6232348 |
Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent
Compounds of formula (I) ##STR1## wherein R, R', R", R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, Y, m, n, and p have the meanings reported in the description; and their pharmaceutically acceptable salts...
|
|
|
6207674 |
Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
Patients can be helped to break free of addictive or habit-forming narcotics and anti-depressants, by treatment using two drugs. One drug is dextromethorphan (DM), which has been used for decades...
|
|
|
6204295 |
Antioxidant compounds
A new use of halogenated triphenylethylene derivatives for lowering levels of serum lipid peroxides and for the prevention or treatment of oxidative tissue damage induced by lipid peroxidation is...
|
|
|
6197789 |
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): ##STR1## wherein Z is CO or a covalent bond; Y is H or O(C 1 -C 4 )alkyl, R 1 and...
|
|
|
6191133 |
Treatment of depression and pharmaceutical preparations therefor
It has been found that the treatment of depression using known serotonin reuptake inhibitors (SRIs) and noradrenaline reuptake inhibitors (NRIs) may be improved by the administration therewith of...
|
|
|
6184222 |
Treatment of conduct disorder
Norepinephrine reuptake inhibitors are used to treat conduct disorder.
|
|
|
6169105 |
Potentiation of drug response
The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination...
|
|
|
6166090 |
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis...
|
|
|
6156723 |
Compositions comprising inhibitors of estrogen response
The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters...
|
|
|
6147072 |
Combination therapy for treatment of psychoses
The invention relates to a method of treating psychosis, acute mania, mild anxiety states or depression in combination with psychotic episodes by administering to a patient a combination of an...
|
|
|
6127425 |
Oral liquid medicine solution
Found is a pharmaceutical preparation which provides Tamoxifen Citrate in a liquid dosage form, viz. as an oral solution. The finding is based on a solvent comprising the following components: (a)...
|
|
|
6124346 |
Estrogen agonist/antagonists treatment of atherosclerosis
A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque....
|
|
|
6114382 |
Methods for treating inflammatory bowel disease
The present invention provides novel compositions and methods relating to the treatment of Inflammatory Bowel Disease ("IBD"), most notably, Ulcerative Colitis, Crohn's Disease, Colitis and...
|
|
|
6096301 |
Combined interferon/antiestrogen therapy for treatment of breast cancer
Proliferation of breast cancer is treated by a combined type I interferon/non-steroidal antiestrogen therapy. Preferably antiestrogen treatment is sequential to treatment with interferon.
|
|
|
6087346 |
Sigma receptor ligands and the use thereof
|
|
|
6071918 |
Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
The invention relates to a method of treating alcoholism and alcohol dependence in a mammal comprising administering to the mammal a therapeutically effective amount of a synergistic combination...
|
|
|
6066643 |
Potentiation of pharmaceuticals
The present invention provides a method for producing a potentiating effect on a therapeutic action of an agent which is selected from a serotonin re-uptake inhibitor, a norepinephrine re-uptake...
|
|
|
6051605 |
Method of treating psychosis and schizophrenia
This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4...
|
|
|
6034091 |
Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
Disclosed herein is a method for treating depression associated with alcoholism in a patient comprising administering to the patient a pharmacologically effective dose of an opioid antagonist, and...
|